

**PB 33 of 2025**

National Health (Originator Brand) Amendment Determination (No. 2) 2025

I, Rebecca Richardson, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make the following Determination.

Dated 27 March 2025

**REBECCA RICHARDSON**

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health and Aged Care

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments 2

National Health (Originator Brand) Determination 2015 (PB 100 of 2015) 2

1 Name

This instrument is the *National Health (Originator Brand) Amendment Determination (No. 2) 2025.*

This instrument may also be cited as PB 33 of 2025.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information | | |
| --- | --- | --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | 1 April 2025 |  |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99ADB(6B) of the *National Health Act 1953.*

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Originator Brand) Determination 2015 (PB 100 of 2015)

1 Schedule 1, (after table item 206)

Insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 206A | Sacubitril with valsartan | Entresto |  |  |

2 Schedule 1, (after table item 228A)

Repeal:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 229 | Tirofiban | Aggrastat |  |  |
| 229A | Tobramycin | DBL Tobramycin  Pfizer Australia Pty Ltd | Injection |  |
| Tobi | Inhalation |  |
| TOBI podhaler | Inhalation by mouth |  |
| Tobrex | Application to the eye |  |
| 229B | Tocilizumab | Actemra  Actemra ACTPen  Actemra Subcutaneous Injection |  |  |

Substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 229 | Tirofiban | Aggrastat |  |  |
| 229A | Tobramycin | DBL Tobramycin  Pfizer Australia Pty Ltd | Injection |  |
| Tobi | Inhalation |  |
| TOBI podhaler | Inhalation by mouth |  |
| Tobrex | Application to the eye |  |
| 229B | Tocilizumab | Actemra  Actemra ACTPen  Actemra Subcutaneous Injection |  |  |
| 229C | Tolvaptan | Jinarc |  |  |